Cite
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
MLA
Schuster, Stephen J., et al. “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” New England Journal of Medicine, vol. 380, no. 1, Jan. 2019, pp. 45–56. EBSCOhost, https://doi.org/10.1056/NEJMoa1804980.
APA
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., & Awasthi, R. (2019). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 380(1), 45–56. https://doi.org/10.1056/NEJMoa1804980
Chicago
Schuster, Stephen J., Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jäger, et al. 2019. “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” New England Journal of Medicine 380 (1): 45–56. doi:10.1056/NEJMoa1804980.